Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours
- 1 August 2002
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (12) , 1615-1621
- https://doi.org/10.1016/s0959-8049(02)00127-2
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- D-21266, a new heterocyclic alkylphospholipid with antitumour activityEuropean Journal Of Cancer, 1997
- Three paths to stress reliefNature, 1996
- Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancerEuropean Journal Of Cancer, 1993
- A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumoursZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Hexadecylphosphocholine in the Topical Treatment of Skin Metastases in Breast Cancer PatientsPublished by S. Karger AG ,1991
- Antitumoral Activity of Alkylphosphocholines and Analogues in Human Leukemia Cell LinesPublished by S. Karger AG ,1991
- Effects of Hexadecylphosphocholine on Cellular FunctionPublished by S. Karger AG ,1991
- Hexadecylphosphocholine, a New Ether Lipid Analogue Studies on the Antineoplastic Activity in Vitro and in VivoActa Oncologica, 1988
- Effect of lipid derivatives on invasion in vitro and on surface glycoproteins of three rodent cell typesLipids, 1987
- Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasionLipids, 1987